Prostate cancer is the second leading cause of cancer death in men in the United States. Novel immunotherapies are being investigated to improve survival in patients with advanced disease. Sipuleucel-T (PROVENGE), the first autologous cellular immunotherapy approved by the U. S. Food and Drug Administration, improves survival in men with asymptomatic or minimally symptomatic metastatic castration-resistant (hormone refractory) prostate cancer.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
prostate cancer
12
improve survival
8
immunotherapy advanced
4
advanced prostate
4
cancer
4
cancer novel
4
novel treatment
4
treatment option
4
option improve
4
survival prostate
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!